Neogen (NEOG) Cash & Equivalents (2010 - 2026)

Neogen has reported Cash & Equivalents for 17 years, with the latest figure at $185.5 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 43.8% year-over-year to $185.5 million in Q2 2026; TTM through May 2026 was $185.5 million, a 43.8% increase from a year earlier, with the FY2026 full-year figure at $185.5 million, up 43.8% from the prior year.
• Cash & Equivalents was $185.5 million for Q2 2026 at Neogen, up from $159.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $205.8 million in Q4 2023, with the low at $42.9 million in Q1 2022.
• Average Cash & Equivalents over 5 years is $132.7 million, with a median of $139.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 41.65% in 2022, then surged 267.05% in 2023.
• Over 5 years, Cash & Equivalents stood at $100.0 million in 2022, then jumped by 105.76% to $205.8 million in 2023, then slumped by 31.85% to $140.2 million in 2024, then grew by 3.64% to $145.3 million in 2025, then climbed by 27.63% to $185.5 million in 2026.
• The last three Cash & Equivalents figures came in at $185.5 million (Q2 2026), $159.9 million (Q1 2026), and $145.3 million (Q4 2025), per Business Quant data.